These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 28102570)

  • 1. Simultaneous determination of free and total prostate-specific antigen by a magnetic particle-based time-resolved fluoroimmunoassay.
    Zhou B; Zhang J; Lv Z; Fan J; Zhang Y; Huang B
    J Clin Lab Anal; 2017 Nov; 31(6):. PubMed ID: 28102570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Magnetic particle-based time-resolved fluoroimmunoassay for the simultaneous determination of α-fetoprotein and the free β-subunit of human chorionic gonadotropin.
    Hou JY; Liu TC; Ren ZQ; Chen MJ; Lin GF; Wu YS
    Analyst; 2013 Jul; 138(13):3697-704. PubMed ID: 23671904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual-label immunoassay for simultaneous measurement of prostate-specific antigen (PSA)-alpha1-antichymotrypsin complex together with free or total PSA.
    Zhu L; Leinonen J; Zhang WM; Finne P; Stenman UH
    Clin Chem; 2003 Jan; 49(1):97-103. PubMed ID: 12507965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of simultaneous detection of total prostate-specific antigen (tPSA) and free PSA with rapid bead-based immunoassay.
    Xie C; Wang G
    J Clin Lab Anal; 2011; 25(1):37-42. PubMed ID: 21254241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A magnetic nanoparticle-based time-resolved fluoroimmunoassay for determination of the cytokeratin 19 fragment in human serum.
    Lin G; Liu T; Hou J; Ren Z; Zhou J; Liang Q; Chen Z; Dong W; Wu Y
    J Fluoresc; 2015 Mar; 25(2):361-7. PubMed ID: 25666714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of an immunomagnetic bead-based time-resolved fluorescence immunoassay for rapid determination of levels of carcinoembryonic antigen in human serum.
    Hou JY; Liu TC; Lin GF; Li ZX; Zou LP; Li M; Wu YS
    Anal Chim Acta; 2012 Jul; 734():93-8. PubMed ID: 22704477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual-labeled chemiluminescence enzyme immunoassay for simultaneous measurement of total prostate specific antigen (TPSA) and free prostate specific antigen (FPSA).
    Zhao L; Wang D; Shi G; Lin L
    Luminescence; 2017 Dec; 32(8):1547-1553. PubMed ID: 28636187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of non-alpha1-antichymotrypsin-complexed prostate-specific antigen as an indirect measurement of free prostate-specific antigen: analytical performance and diagnostic accuracy.
    Wesseling S; Stephan C; Semjonow A; Lein M; Brux B; Sinha P; Loening SA; Jung K
    Clin Chem; 2003 Jun; 49(6 Pt 1):887-94. PubMed ID: 12765984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Percent free PSA as an additional measure in a prostate cancer screen.
    Miele ME
    Clin Lab Sci; 2001; 14(2):102-7. PubMed ID: 15625982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Age-specific reference ranges for prostate-specific antigen (PSA) in Jordanian patients.
    Battikhi MN
    Prostate Cancer Prostatic Dis; 2003; 6(3):256-60. PubMed ID: 12970732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous quantitation of carbohydrate antigen 125 and carcinoembryonic antigen in human serum via time-resolved fluoroimmunoassay.
    Huang Z; Zhai XM; Wang H; Deng QT; Li K; Liu BS; Wang G; Liu TC
    Clin Chim Acta; 2018 Aug; 483():222-226. PubMed ID: 29729233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater.
    Becker C; Piironen T; Pettersson K; Hugosson J; Lilja H
    Urology; 2000 May; 55(5):694-9. PubMed ID: 10792083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum half-life time determination of free and total prostate-specific antigen following radical prostatectomy--a critical assessment.
    Brändle E; Hautmann O; Bachem M; Kleinschmidt K; Gottfried HW; Grünert A; Hautmann RE
    Urology; 1999 Apr; 53(4):722-30. PubMed ID: 10197847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a novel immunoassay for the simple and fast quantitation of neutrophil gelatinase-associated lipocalin using europium(III) chelate microparticles and magnetic beads.
    Wang H; Zhai X; Liu T; Liang J; Bian L; Lin L; Chen Z; Li P; Dong Z; Li Z; Wu Y
    J Immunol Methods; 2019 Jul; 470():15-19. PubMed ID: 31004578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml.
    Haese A; Graefen M; Steuber T; Becker C; Pettersson K; Piironen T; Noldus J; Huland H; Lilja H
    Prostate; 2001 Oct; 49(2):101-9. PubMed ID: 11582588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A magnetic nanoparticle-labeled immunoassay with europium and samarium for simultaneous quantification of serum pepsinogen I and II.
    Fan J; Xiao H; Zhang J; Zhou B; Deng L; Zhang Y; Huang B
    Br J Biomed Sci; 2017 Jul; 74(3):127-132. PubMed ID: 28521643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a dual-label time-resolved fluoroimmunoassay for the detection of α-fetoprotein and hepatitis B virus surface antigen.
    Lin GF; Liu TC; Zou LP; Hou JY; Wu YS
    Luminescence; 2013; 28(3):401-6. PubMed ID: 22715159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Percentage of free serum prostate-specific antigen: a new tool in the early diagnosis of prostatic cancer.
    Toubert ME; Guillet J; Chiron M; Meria P; Role C; Schlageter MH; Francois H; Borschneck C; Nivelon F; Desgrandchamps F; Rastel D; Cussenot O; Teillac P; Le Duc A; Najean Y
    Eur J Cancer; 1996 Nov; 32A(12):2088-93. PubMed ID: 9014750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of alpha1-antichymotrypsin-PSA complex in serum does not improve the differentiation between benign prostatic hyperplasia and prostate cancer compared with total PSA and percent free PSA.
    Jung K; Brux B; Lein M; Knäbich A; Sinha P; Rudolph B; Schnorr D; Loening SA
    Urology; 1999 Jun; 53(6):1160-7; discussion 1167-8. PubMed ID: 10367846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparisons of the various combinations of free, complexed, and total prostate-specific antigen for the detection of prostate cancer.
    Okegawa T; Noda H; Nutahara K; Higashihara E
    Eur Urol; 2000 Oct; 38(4):380-7. PubMed ID: 11025374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.